PRTN3 and rheumatoid arthritis: In contrast, Hedström et al. conducted a case–control study with 3655 cases and 5883 controls from a Swedish population [52], in which they found a dose-dependent increase of RA risk in both ACPA-positive and -negative cases, with greater effects in ACPA-positive cases.